title: Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.
authors.affiliation: Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland.
authors.forename: Ali
authors.initials: A
authors.lastname: Sigaroudi
authors.affiliation: Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland.
authors.forename: Gerd A
authors.initials: GA
authors.lastname: Kullak-Ublick
authors.affiliation: Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland. stefan.weiler@usz.ch.
authors.forename: Stefan
authors.initials: S
authors.lastname: Weiler
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D000078330:Oxcarbazepine; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: C523327:10-monohydroxycarbazepine; D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D002220:Carbamazepine; D012293:Rifampin; D000078330:Oxcarbazepine